Pharmacyclics shareholder Robert Duggan steps in after CEO, board members resign

By Lisa Kerner

Charlotte, N.C., Sept. 17 - Pharmacyclics, Inc. investor Robert W. Duggan was named interim chief executive officer after CEO Richard Miller resigned, according to a schedule 13D/A filed with the Securities and Exchange Commission.

Pharmacyclics vice president and chief financial officer Leiv Lea also resigned, effective Oct. 31.

Duggan, a 29% shareholder and recently named chairman of the board, intends to nominate four candidates to the board following the resignations of Christine A. White, Richard M. Levy, Miles R. Gilburne and Richard A. Miller on Sept. 10.

The board appointed Minesh Mehta, M.D., and Glenn C. Rice, Ph.D., to immediately fill two vacancies and said it will appoint Cynthia Bamdad, Ph.D., and David Smith, Ph.D., to the board following the expiration of a 10-day period required by rule 14f-1 under the Securities Exchange Act of 1934, as amended.

Based in Sunnyvale, Calif., Pharmacyclics is a pharmaceutical company focused on cancer and other serious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.